(2025). ALTAIR Study: Trifluridine/Tipiracil vs Placebo in Patients With Molecular Residual Disease Following Curative Resection of CRC. Clinical advances in hematology & oncology: H&O, 23, 11.
Chicago Style (17th ed.) Citation"ALTAIR Study: Trifluridine/Tipiracil Vs Placebo in Patients With Molecular Residual Disease Following Curative Resection of CRC." Clinical Advances in Hematology & Oncology: H&O 23 (2025): 11.
MLA (9th ed.) Citation"ALTAIR Study: Trifluridine/Tipiracil Vs Placebo in Patients With Molecular Residual Disease Following Curative Resection of CRC." Clinical Advances in Hematology & Oncology: H&O, vol. 23, 2025, p. 11.
Warning: These citations may not always be 100% accurate.
